Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Žilvinas Venclovas"'
Autor:
Daimantas Milonas, Žilvinas Venclovas, Inga Gudinaviciene, Stasys Auskalnis, Kristina Zviniene, Nemira Jurkiene, Algidas Basevicius, Ausvydas Patasius, Mindaugas Jievaltas, Steven Joniau
Publikováno v:
Frontiers in Oncology, Vol 9 (2019)
Objective: To investigate the relationship between the new International Society of Urological Pathology (ISUP) grading system, biochemical recurrence (BCR), clinical progression (CP) and cancer related death (CRD) after open radical prostatectomy (R
Externí odkaz:
https://doaj.org/article/4e1ec9a4650a4e9cb84cb9aa50e3a548
Autor:
Daimantas Milonas, Alexander Giesen, Tim Muilwijk, Charlotte Soenens, Gaëtan Devos, Zilvinas Venclovas, Alberto Briganti, Paolo Gontero, R. Jeffrey Karnes, Piotr Chlosta, Frank Claessens, Gert De Meerleer, Wouter Everaerts, Markus Graefen, Giansilvio Marchioro, Rafael Sanchez-Salas, Bertrand Tombal, Henk Van Der Poel, Hendrik Van Poppel, Martin Spahn, Steven Joniau
Publikováno v:
European Urology Open Science, Vol 66, Iss , Pp 33-37 (2024)
International Society of Urological Pathology grade group 1 (GG 1) prostate cancer (PCa) is generally considered insignificant, with recent suggestions that it should even be considered as “noncancerous”. We evaluated outcomes for patients with G
Externí odkaz:
https://doaj.org/article/c8d0ad4edb444a3cbd022eb478d1fc4d
Autor:
Zilvinas Venclovas, Aurelija Alksnyte, Urte Rimsaite, Tomas Navickis, Mindaugas Jievaltas, Daimantas Milonas
Publikováno v:
Medicina, Vol 60, Iss 6, p 885 (2024)
Introduction: Renal haemangioma is a benign tumour, and due to its characteristics, it must be distinguished from malignant diseases. We present a clinical case of primary renal angiosarcoma initially mistaken for haemangioma due to their similarity.
Externí odkaz:
https://doaj.org/article/25d02695ba6e43af962561d36c70f907
Publikováno v:
Frontiers in Oncology, Vol 9 (2019)
Objective: The aim of our study was to evaluate the impact of time until biochemical recurrence (BCR) after radical prostatectomy (RP) without neo- or adjuvant treatment on clinical progression (CP) and cancer-related death (CRD) in high-risk prostat
Externí odkaz:
https://doaj.org/article/3620fb1a49904091a3890b883d1bc3db